Loading clinical trials...
Loading clinical trials...
Prospective Study of Deep Brain Stimulation With the VERCISE™ System for Treatment of Dystonia
To compile characteristics of real-world outcomes of Boston Scientific Corporation's commercially approved VerciseTM Deep Brain Stimulation (DBS) Systems for the treatment of dystonia.
To compile characteristics of real-world outcomes of Boston Scientific Corporation's commercially approved VerciseTM Deep Brain Stimulation (DBS) Systems for the treatment of dystonia. Subjects' improvement in disease symptoms and overall Quality of life will be assessed.
Age
7 - No limit years
Sex
ALL
Healthy Volunteers
No
AZ Sint-Lucas
Ghent, Belgium
UZ Gasthuisberg
Leuven, Belgium
Queen Elizabeth II Health Sciences Center
Halifax, Canada
University Berlin, Charite Virchow Standort, Wedding
Berlin, Germany
Uniklinik Köln
Cologne, Germany
Universitaetsklinikum Dusseldorf
Düsseldorf, Germany
Universitaetsklinikum Freiburg
Freiburg im Breisgau, Germany
Universitaetsklinik Eppendorf
Hamburg, Germany
St. Barbara-Klinik Hamm-Heessen
Hamm, Germany
Medizinische Hochschule Hannover MHH
Hanover, Germany
Start Date
March 7, 2016
Primary Completion Date
December 1, 2030
Completion Date
December 1, 2030
Last Updated
March 12, 2026
300
ESTIMATED participants
Deep Brain Stimulation (DBS)
DEVICE
Lead Sponsor
Boston Scientific Corporation
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT01581580